Literature DB >> 22240606

Critical role of CD4(+)CD25(+) regulatory T cells in preventing murine autoantibody-mediated thrombocytopenia.

Tetsuya Nishimoto1, Takashi Satoh, Tsutomu Takeuchi, Yasuo Ikeda, Masataka Kuwana.   

Abstract

Autoimmune response suppression by regulatory T cells (Tregs) helps to maintain peripheral immune tolerance, and defects in this mechanism are thought to play a role in the pathogenesis of various autoimmune diseases. In patients with immune thrombocytopenia, naturally occurring CD4(+)CD25(+) Tregs are both functionally impaired and reduced in number. This study was undertaken to investigate Tregs' role in preventing immune thrombocytopenia in mice. Treg-deficient mice were prepared by inoculation of Treg-depleted CD4(+)CD25(-) T cells isolated from BALB/c mice into syngeneic nude mice intravenously. Platelet count, proportion of reticulated platelets, platelet-associated IgG, platelet-associated anti-platelet antibodies, and IgG anti-platelet antibody production in splenocyte cultures were examined by flow cytometry. Of 69 Treg-deficient mice, 25 (36%) spontaneously developed thrombocytopenia that lasted at least 5 weeks. The platelet-associated IgG level and proportion of reticulated platelets were elevated in the thrombocytopenic mice. Platelet eluates and splenocyte culture supernatants prepared from thrombocytopenic mice, but not from nonthrombocytopenic mice, contained IgG antibodies capable of binding to intact platelets. Simultaneous transfer of Tregs completely prevented the onset of thrombocytopenia, but Treg transfer after the onset of thrombocytopenia had no apparent effect. Treatment with IgG anti-cytotoxic T lymphocyte-associated antigen 4 antibody canceled this Treg-governed suppressive effect. In summary, these results indicate that Tregs play a critical role in preventing murine autoantibody-mediated thrombocytopenia by engaging cytotoxic T lymphocyte-associated antigen 4. Copyright Â
© 2012 ISEH - Society for Hematology and Stem Cells. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22240606     DOI: 10.1016/j.exphem.2012.01.001

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  11 in total

1.  CD8+ T cells are predominantly protective and required for effective steroid therapy in murine models of immune thrombocytopenia.

Authors:  Li Ma; Elisa Simpson; June Li; Min Xuan; Miao Xu; Laura Baker; Yan Shi; Issaka Yougbaré; Xiaozhong Wang; Guangheng Zhu; Pingguo Chen; Gerald J Prud'homme; Alan H Lazarus; John Freedman; Heyu Ni
Journal:  Blood       Date:  2015-06-02       Impact factor: 22.113

2.  Circulating level of Th17 cells is associated with sensitivity to glucocorticoids in patients with immune thrombocytopenia.

Authors:  YiChan Zhang; TingTing Ma; Xuan Zhou; JunHao Chen; Juan Li
Journal:  Int J Hematol       Date:  2018-01-11       Impact factor: 2.490

3.  TGF-β1 along with other platelet contents augments Treg cells to suppress anti-FVIII immune responses in hemophilia A mice.

Authors:  Dipica Haribhai; Xiaofeng Luo; Juan Chen; Shuang Jia; Linzheng Shi; Jocelyn A Schroeder; Hartmut Weiler; Richard H Aster; Martin J Hessner; Jianda Hu; Calvin B Williams; Qizhen Shi
Journal:  Blood Adv       Date:  2016-12-13

4.  Mouse immune thrombocytopenia is associated with Th1 bias and expression of activating Fcγ receptors.

Authors:  Tetsuya Nishimoto; Yuka Okazaki; Miku Numajiri; Masataka Kuwana
Journal:  Int J Hematol       Date:  2016-12-27       Impact factor: 2.490

Review 5.  Pathophysiology and management of primary immune thrombocytopenia.

Authors:  Hirokazu Kashiwagi; Yoshiaki Tomiyama
Journal:  Int J Hematol       Date:  2013-05-24       Impact factor: 2.490

6.  A novel canine model of immune thrombocytopenia: has immune thrombocytopenia (ITP) gone to the dogs?

Authors:  Dana N LeVine; Adam J Birkenheuer; Marjory B Brooks; Shila K Nordone; Dwight A Bellinger; Sam L Jones; Thomas H Fischer; Stephen E Oglesbee; Kahlina Frey; Nicole S Brinson; Allison P Peters; Henry S Marr; Alison Motsinger-Reif; Sif Gudbrandsdottir; James B Bussel; Nigel S Key
Journal:  Br J Haematol       Date:  2014-07-08       Impact factor: 6.998

7.  Induction of immune tolerance to platelet antigen by short-term thrombopoietin treatment in a mouse model of immune thrombocytopenia.

Authors:  Tetsuya Nishimoto; Miku Numajiri; Hisataka Nakazaki; Yuka Okazaki; Masataka Kuwana
Journal:  Int J Hematol       Date:  2014-09-12       Impact factor: 2.490

8.  Changes in follicular helper T cells in idiopathic thrombocytopenic purpura patients.

Authors:  Jue Xie; Dawei Cui; Yan Liu; Jie Jin; Hongyan Tong; Lei Wang; Guoxiang Ruan; Yun Lu; Huiming Yuan
Journal:  Int J Biol Sci       Date:  2015-01-05       Impact factor: 6.580

9.  Circulating myeloid-derived suppressor cells predict disease activity and treatment response in patients with immune thrombocytopenia.

Authors:  J Zhou; Y Zhou; J Wen; X Sun; X Zhang
Journal:  Braz J Med Biol Res       Date:  2017-02-16       Impact factor: 2.590

10.  Long-lasting response to afatinib that persisted after treatment discontinuation in a case of EGFR-mutated lung adenocarcinoma.

Authors:  Yumie Yamanaka; Yoshitaka Seki; Takeo Ishikawa; Kazuyoshi Kuwano
Journal:  BMJ Case Rep       Date:  2019-01-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.